Biotech

Nanollose Limited (ASX:NC6) Successful Completion of Denim Production at Orta

🕔12/1/2022 8:15:54 AM

Nanollose Limited (ASX:NC6) (FRA:N0L) is pleased to advise that Orta Anadolu Ticaret Ve Sanayi Isletmesi T.A.S. ("ORTA") has successfully manufactured sample yardage of high-quality denim fabric containing the Company's Nullarbor-20(TM) fibre.

Read Full Article

Nanollose Limited (ASX:NC6) Successful Completion of Fabric Production at Paradise

🕔11/2/2022 8:29:23 AM

Nanollose Limited (ASX:NC6) (FRA:N0L) is pleased to provide shareholders with the following update on its collaboration with Paradise Textiles Limited.

Read Full Article

Nanollose Limited (ASX:NC6) Quarterly Activities Report

🕔10/31/2022 9:03:29 AM

Nanollose Limited (ASX:NC6) (FRA:N0L) a leading bio-materials company, focused on commercialising scalable technology to create fibres and fabrics with minimal environmental impact, is pleased to provide shareholders with an overview of its activities for the period ended 30 September 2022.

Read Full Article

Apiam Animal Health Limited (ASX:AHX) Investor Update

🕔10/20/2022 8:36:27 AM

Apiam Animal Health Limited (ASX:AHX) has expanded in Western Australia, via the acquisition of Harradine & Associates announced last week.

Read Full Article

VGI Health Technology Limited (NSX:VTL) R & D Facility Agreement with Fundsquire Pty Ltd

🕔10/13/2022 3:26:00 PM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has entered into an R&D Loan Facility Agreement (Loan Facility) with Fundsquire Pty Ltd.

Read Full Article

Apiam Animal Health Limited (ASX:AHX) Acquisition of Harradine & Associates Veterinary Business

🕔10/12/2022 9:26:49 AM

Apiam Animal Health Limited (ASX:AHX) is pleased to announce the acquisition of Harradine & Associates, a large veterinary business located in the southwest region of Western Australia.

Read Full Article

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH Phase II Clinical Study

🕔10/5/2022 8:58:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced dosing of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease.

Read Full Article